why choose us

Clinical Trials Search

Showing 8,490 of 132,366 result(s)
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

Status: Completed

Condition: Ulcerative Colitis

Interventions: Tablets administered orally

Date: 2023-09-01

Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US

Status: Completed

Condition: Liver Fibrosis

Interventions: The examination with iLivTouch will be performed in each subject following the sequence determined by the randomization results.

Date: 2023-09-01

A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants

Status: Completed

Condition: Healthy

Interventions: Administered orally.

Date: 2023-09-01

Heart Failure Polypill at a Safety Net Hospital

Status: NOT_YET_RECRUITING

Condition: Heart Failure With Reduced Ejection Fraction

Interventions: Copackaging of once-daily heart failure medications (beta blocker, SGLT2i, and MRA) in an overencapsulated polypill.
Individual tablets will be h

Date: 2023-09-01

A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).

Status: NOT_YET_RECRUITING

Condition: ATTR-CM

Interventions: Software to calculate the predicted probability of ATTRwt-CM for these heart failure patients based on the presence and absence of certain features

Date: 2023-09-01

Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder

Status: Completed

Condition: Major Depressive Disorder

Interventions: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally

Date: 2023-09-01

Study to Assess the Safety and Effectiveness of NMRA-335140-501

Status: Completed

Condition: Major Depressive Disorder

Interventions: Participants will receive NMRA-335140 at a dose of 80 mg once daily (QD), orally during a 52-week treatment period.

Date: 2023-09-01

Spatial-Motor Stroke-Rehab Study

Status: Completed

Condition: Spatial Neglect

Interventions: PAT requires one to wear prism lenses while making arm-reaching movements toward visual targets.
For treating left-sided neglect, a person wears

Date: 2023-09-01

Pembrolizumab;Lenvatinib With and Without Responder-derived FMT in Relapsed;Refractory Melanoma

Status: NOT_YET_RECRUITING

Condition: PD-1 Refractory Advanced Melanoma

Interventions: R-FMT (induction) via colonoscopy on C1D1 and C3D1.
R-FMT (maintenance) via sigmoidoscopy will be repeated every 9 weeks.

Date: 2023-09-01

Stroke and CPAP Outcome Study 3

Status: Completed

Condition: Ischemic Stroke

Interventions: Eligible participants with a diagnosis of OSA will be set up with autotitrating CPAP by the study's sleep technologist.
The CPAP device incl

Date: 2023-09-01